Two populations of muscarinic binding sites in the chick heart distinguished by affinities for ligands and selective inactivation.
1. By measuring the binding of N-[3H-methyl]-scopolamine ([3H]-NMS) and of unlabelled subtype-specific muscarinic antagonists, two populations of muscarinic binding sites can be distinguished in the membranes of cardiac ventricles taken from 1-day-old chicks. One of them, corresponding to approximately 80% of [3H]-NMS binding sites, has higher affinities for AF-DX116 (pKi = 6.42) and methoctramine (pKi = 7.33); the rate of [3H]NMS dissociation from these sites is fast. The other population, corresponding to approximately 20% of [3H]-NMS binding sites, has lower affinities for AF-DX116 (pKi = 5.00) and methoctramine (pKi = 6.19); the rate of [3H]-NMS dissociation from these sites is slow. Both populations have high affinities for pirenzepine, but the affinity of the former (major) population is lower (pKi = 7.99) than that of the latter (minor) population (pKi = 10.14). 2. Since it has been shown earlier that two mRNAs for muscarinic receptors are expressed in the chick heart, one of them close to the genetically defined m2 and the other to the m4 subtype, we propose that the major population of binding sites with high affinities for AF-DX116 and methoctramine and the lower affinity for pirenzepine represents the M2-like receptors, while the minor population represents the M4-like receptors. 3. It proved possible to obtain isolated samples of either population by selectively protecting the M2-like sites with AF-DX116 and the M4-like sites with pirenzepine, and by inactivating the unprotected sites with benzilylcholine mustard. The properties of the isolated populations corresponded to those derived from the analysis of [3H]-NMS binding to the original mixed population.4 Alcuronium exerted positive allosteric action on the binding of [3H]-NMS both to the M2-like and the M4-like population and severely slowed down [3H]-NMS dissociation from them; its affinity for the M2-like sites was 3-10 times higher.
Jakubík
J
J
Institute of Physiology, Academy of Sciences of the Czech Republic, Prague.
Tucek
S
S
D000443:Alcuronium / Q000493:pharmacokinetics; D000818:Animals; D002645:Chickens; D002794:Choline / Q000031:analogs & derivatives; D018678:Cholinergic Agents; D003959:Diamines / Q000493:pharmacokinetics; D005260:Female; D066298:In Vitro Techniques; D008024:Ligands; D008297:Male; D018727:Muscarinic Antagonists; D009206:Myocardium / Q000378:metabolism*; D019832:N-Methylscopolamine; D010276:Parasympatholytics / Q000494:pharmacology; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D012333:RNA, Messenger / Q000378:metabolism; D011869:Radioligand Assay; D051381:Rats; D017208:Rats, Wistar; D011976:Receptors, Muscarinic / Q000378:metabolism*; D012602:Scopolamine Derivatives / Q000493:pharmacokinetics
D018678:Cholinergic Agents; D003959:Diamines; D008024:Ligands; D018727:Muscarinic Antagonists; D010276:Parasympatholytics; D012333:RNA, Messenger; D011976:Receptors, Muscarinic; D012602:Scopolamine Derivatives; D010890:Pirenzepine; C100238:benzilylcholine mustard; D002794:Choline; C054938:methoctramine; C048593:otenzepad; D000443:Alcuronium; D019832:N-Methylscopolamine